Balancing Safety and Efficacy With Key Data
December 5th 2024James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.
The JAK Revolution in Vitiligo
December 5th 2024James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.
Promising and Emerging Therapies in the Vitiligo Landscape
December 5th 2024James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.